Generate Biomedicines today announced that it will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco later this month.
Mike Nally, Generate’s Chief Executive Officer, is scheduled to present the company’s vision for 2023 and beyond on Jan. 12 at 9:30 a.m. PT (12:30 p.m. ET) in the Golden Gate Room on the 31st floor of the Westin St. Francis, 335 Powell St.
Generate’s management, investor relations and business development leadership will be attending and available throughout the conference for meetings.
About Generate Biomedicines
Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company’s platform represents a potentially fundamental shift in what’s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020. Learn more about Generate Biomedicines by visiting https://generatebiomedicines.com/ or following the company on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005656/en/
Contacts
Media
Megan McLaughlin
pr@generatebiomedicines.com
